vTv Therapeutics (VTVT) Other Non-Current Liabilities (2014 - 2022)
vTv Therapeutics recorded quarterly Other Non-Current Liabilities of $770000.0 in Q1 2022, down 38.99% quarter-over-quarter from $1.3 million in Q4 2021, and up 1440.0% year-over-year from $50000.0 in Q1 2021.
vTv Therapeutics' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $770000.0 for Q1 2022.
- In Q1 2022, Other Non-Current Liabilities rose 1440.0% year-over-year to $770000.0; the TTM figure through Mar 2022 stood at $770000.0 (up 1440.0% YoY), while the FY2021 annual figure was $1.3 million, up 2424.0% from the prior year.
- Other Non-Current Liabilities came in at $770000.0 for Q1 2022 at vTv Therapeutics, down from $1.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 million in Q4 2021 to a low of $50000.0 in Q4 2020.
- A 5-year average of $276294.1 and a median of $258000.0 in 2018 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities sank 80.77% in 2020 and surged 2424.0% in 2021, its largest moves.
- vTv Therapeutics' Other Non-Current Liabilities stood at $260000.0 in 2018, then changed by 0.0% to $260000.0 in 2019, then tumbled by 80.77% to $50000.0 in 2020, then soared by 2424.0% to $1.3 million in 2021, then slumped by 38.99% to $770000.0 in 2022.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $770000.0, $1.3 million, and $50000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | vTv Therapeutics | 413.85 Mn | 413.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 770,000.00 |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 50,000.00 |
| Sep 30, 2020 | 82,000.00 |
| Jun 30, 2020 | 54,000.00 |
| Mar 31, 2020 | 260,000.00 |
| Dec 31, 2019 | 260,000.00 |
| Sep 30, 2019 | 260,000.00 |
| Jun 30, 2019 | 260,000.00 |
| Mar 31, 2019 | 260,000.00 |
| Dec 31, 2018 | 260,000.00 |
| Sep 30, 2018 | 258,000.00 |
| Jun 30, 2018 | 256,000.00 |
| Mar 31, 2018 | 255,000.00 |
| Dec 31, 2017 | 290,000.00 |
| Sep 30, 2017 | 285,000.00 |
| Jun 30, 2017 | 273,000.00 |
| Mar 31, 2017 | 269,000.00 |
| Dec 31, 2016 | 433,000.00 |
| Dec 31, 2015 | 245,000.00 |
| Sep 30, 2015 | 53,000.00 |
| Jun 30, 2015 | 150.00 Mn |
| Dec 31, 2014 | 4.43 Mn |